Pfizer Inc 8-K, filed Mar 4, 2020
Pfizer Inc (PFE)
8-K
2020-03-04
For: 2020-03-03
View Original
Added on
April 10, 2026
About this 8-K
Pfizer Inc filed this 8-K on March 4, 2020, reporting on events of March 3, 2020.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 3, 2020
(Exact name of registrant as specified in its charter)
(State or other | (Commission File | (I.R.S. Employer |
jurisdiction of | Number) | Identification No.) |
incorporation) | ||
(Zip Code) | ||
(Address of principal executive offices)
Registrant’s telephone number, including area code:
(212 ) 733-2323
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Securities registered pursuant to Section 12(b) of the Act: | ||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Election of Dr. Susan Hockfield to the Board of Directors
On March 3, 2020, the Board of Directors (the “Board”) of Pfizer Inc. (the “Company”) elected Susan Hockfield to serve as a member of the Company’s Board, effective immediately. In addition, she was elected to the Regulatory and Compliance Committee and the Science and Technology Committee of the Board.
Dr. Hockfield has been provided an indemnification agreement and will receive compensation in accordance with the Company’s standard arrangements for non-employee directors.
The press release, dated March 4, 2020, announcing the election of Dr. Hockfield is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit | Description | |||
Press Release dated March 4, 2020 | ||||
104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. | |||
Exhibit Index
Exhibit Number | Description |
Press Release dated March 4, 2020 | |
104 | Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PFIZER INC. | ||
Dated: March 4, 2020 | By: | /s/ Margaret M. Madden |
Margaret M. Madden | ||
Senior Vice President and Corporate Secretary | ||
Chief Governance Counsel | ||
Exhibit 99.1 | ||||
 | ||||
Contacts: Media Relations: | Patricia Kelly +1 (212) 733-3810 Patricia.Kelly@Pfizer.com | |||
Investor Relations | Ryan Crowe +1 (212) 733-8160 Ryan.Crowe@Pfizer.com | |||
March 4, 2020
SUSAN HOCKFIELD ELECTED TO PFIZER’S BOARD OF DIRECTORS
NEW YORK, March 4, 2020—Pfizer Inc. (NYSE: PFE) today announced the election of Dr. Susan Hockfield to its Board of Directors, effective immediately. Dr. Hockfield, age 68, was also appointed to the Regulatory and Compliance Committee and the Science and Technology Committee of Pfizer’s Board.
Dr. Hockfield is Professor of Neuroscience and President Emerita at the Massachusetts Institute of Technology (MIT). She served as MIT’s sixteenth president from 2004 to 2012 and was the first woman and the first life scientist to lead MIT. She is also a member of the Koch Institute for Integrative Cancer Research at MIT. Prior to joining MIT, she was the William Edward Gilbert Professor of Neurobiology, Dean of the Graduate School of Arts and Sciences from 1998 to 2002 and Provost from 2003 to 2004 at Yale University.
She is also a member of the American Association for the Advancement of Sciences (where she served as President-elect, President and Chair), the American Academy of Arts and Sciences, and the Society for Neuroscience.
1
Dr. Hockfield served as Science Envoy with the U.S. Department of State and as a member of a Congressional Commission evaluating the Department of Energy laboratories.
She served as a Director of General Electric Company from 2006 until 2018 and Director of Qualcomm from 2012 until 2016.
Dr. Hockfield received a B.S. in Biology from the University of Rochester and a Ph.D. in Anatomy and Neuroscience from Georgetown University School of Medicine.
“We are fortunate to welcome Dr. Susan Hockfield to Pfizer’s Board of Directors,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “We continue to infuse our Board with scientific expertise in support of our strategic focus on innovation and advancing our pipeline. As a distinguished neuroscientist and highly respected academic leader, Dr. Hockfield will bring tremendous value to the company and our shareholders.”
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
2